Lokon Pharma

Lokon Pharma is a clinical-stage biotech company pioneering immunostimulatory gene therapy for oncology. Its lead platform, the LOAd family of oncolytic adenoviruses, is engineered to modify the tumor microenvironment and stimulate anti-cancer immunity. The company has completed multiple Phase I/II trials in pancreatic cancer, melanoma, and other solid tumors, and has secured strategic collaborations with major pharmaceutical players like Roche. Lokon is positioning its lead candidate, LOAd703, for later-stage development, supported by FDA Fast Track Designation in pancreatic cancer.

LOAd platform of tumor microenvironment (TME) gene engineering vectors: oncolytic adenoviruses armed with immunostimulatory genes (e.g., 4-1BBL, CD40L) designed to selectively infect tumors and stimulate anti-cancer immunity.

Lokon competes in the oncolytic virus space with companies like Amgen (T-VEC) and in the broader tumor microenvironment modulation field. Its differentiation lies in its specific armed adenovirus design (4-1BBL/CD40L). It faces competition from other immunotherapy modalities (cell therapies, bispecific antibodies) also targeting cold tumors.